---
title: "Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies"
description: "Formulary evidence on Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies. Clinical evidence covers EMBOLD, EMERALD, Single-patient emergency use: new zealand, Single-patient emergency use: Germany, PRAX-562-101, and PRAX-562-102. 170 evidence topics quoted from 68 sources. Every quote links to the document it came from."
canonical: "https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies"
published: "2026-09-14T15:39:06-04:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies

<a id="executive-summary"></a>

## 1 Executive Summary

<a id="heading-1.1"></a>

### 1.1 Clinical Benefits of Relutrigine

<a id="heading-1.1.1"></a>

#### 1.1.1 Burden of SCN2A- and SCN8A-related developmental and epileptic encephalopathies

<a id="topic-1.1.1-1"></a>

##### Summary

The disease burden includes early-onset seizures, developmental impairment, and substantial treatment exposure. In a SCN2A-related disorder cohort, developmental delay or intellectual disability was present in 91 of 100 participants. In a SCN8A caregiver survey, 77% were taking at least two antiseizure medications and 50% had previously tried and stopped at least four. A separate SCN8A mortality study reported 5.3% mortality among 190 participants. These estimates come from different populations and should not be treated as a single cohort.

Source: [Goad et al. (2025)](https://portal.findresearcher.sdu.dk/en/publications/development-and-adaptive-function-in-individuals-with-scn2a-relat/); [Cutts et al. (2022)](https://pubmed.ncbi.nlm.nih.gov/35325842/); [Johannesen et al. (2018)](https://pubmed.ncbi.nlm.nih.gov/29677576/)

<a id="heading-1.1.2"></a>

#### 1.1.2 Relutrigine Efficacy and Safety

<a id="topic-1.1.2-1"></a>

##### Summary

EMBOLD randomized 16 participants in cohort 1 and 53 in cohort 2. Reported placebo-adjusted motor seizure reductions over 16 weeks were 46% in cohort 1 and 53% in the confirmatory cohort. Cohort 1 adverse events included infections, vomiting, pyrexia, somnolence, and constipation. The healthy-volunteer PRAX-562-102 combination study is a separate safety dataset: one participant experienced three study-drug-related serious adverse events, and Part B stopped early.

Source: [Praxis Precision Medicines EMBOLD topline results announcement (2024)](https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-announces-positive-topline-results-0); [Kamireddy et al. (2026a)](https://praxismedicines.com/aan2026-10-010/); [Kamireddy et al. (2025a)](https://praxismedicines.com/aes138/); [Pfister et al. (2023a)](https://praxismedicines.com/wp-content/uploads/2024/07/IEC2023_562-102_Final_QRcode.pdf)

<a id="heading-1.1.3"></a>

#### 1.1.3 Budget Impact of Relutrigine

<a id="topic-1.1.3-1"></a>

##### Summary

The available economic material is a U.S. sales forecast, ranging from $5 million in 2026 to $685 million in 2030. These figures describe projected sales, not a payer budget-impact model or annual treatment cost per participant.

Source: [Prime Therapeutics (2026)](https://www.primetherapeutics.com/quarterly-drug-pipeline-july-2026)

<a id="heading-1.1.4"></a>

#### 1.1.4 Conclusions

<a id="topic-1.1.4-1"></a>

##### Summary

The randomized EMBOLD evidence supports reduced motor seizure frequency in the studied SCN2A- and SCN8A-DEE populations. Longer-term seizure reduction is reported from an open-label extension involving 13 participants, which lacks a concurrent placebo comparison. Relutrigine remains investigational; the updated FDA target action date is December 27, 2026. Reported seizure outcomes do not, by themselves, establish improvement in health-related quality of life.

Source: [Kamireddy et al. (2025a)](https://praxismedicines.com/aes138/); [Kamireddy et al. (2025b)](https://aesnet.org/abstractslisting/relutrigine-demonstrates-sustained-seizure-reduction-with-continued-exposure-on-top-of-standard-of-care-results-from-the-embold-open-label-extension); [The Cute Syndrome Foundation](https://www.thecutesyndrome.com/clinicaltrials.html); [Praxis Precision Medicines extension period announcement (2026)](https://www.globenewswire.com/news-release/2026/06/29/3319308/0/en/praxis-precision-medicines-announces-extension-period-for-relutrigine-for-treatment-of-scn2a-and-scn8a-developmental-and-epileptic-encephalopathies.html); [Cohen et al. (2022)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10305579/)

## Related pages
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Terms and abbreviations](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/terms-and-abbreviations.md)
- [Relutrigine: SCN2A- and SCN8A-related developmental and epileptic encephalopathies](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/executive-summary.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Product information and disease description](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/product-information-and-disease-description.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Clinical evidence](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/clinical-evidence.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: Economic information and modeling report](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/economics.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: References](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/references.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: prevalence by geography](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/prevalence.md)
- [Relutrigine in SCN2A- and SCN8A-related developmental and epileptic encephalopathies: cost-effectiveness analyses and utility weights](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses) · [Markdown](https://www.evicenter.com/drugs/relutrigine--scn2a-and-scn8a-related-developmental-and-epileptic-encephalopathies/cost-effectiveness-analyses.md)
